Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22544182.
- Also identified by DOI 10.1093/cid/cis206 and PMC identifier 3338313.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The HIV drug resistance (HIVDR) prevention and assessment strategy, developed by the World Health Organization (WHO) in partnership with HIVResNet, includes monitoring of HIVDR early warning indicators, surveys to assess acquired and transmitted HIVDR, and development of an accredited HIVDR genotyping laboratory network to support survey implementation in resource-limited settings. As of June 2011, 52 countries had implemented at least 1 element of the strategy, and 27 laboratories had been accredited. As access to antiretrovirals expands under the WHO/Joint United Nations Programme on HIV/AIDS Treatment 2.0 initiative, it is essential to strengthen HIVDR surveillance efforts in the face of increasing concern about HIVDR emergence and transmission.
Medical subject headings
- Anti-Retroviral Agents
- HIV Infections
- Health Policy